{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:04:13Z","timestamp":1774368253479,"version":"3.50.1"},"reference-count":7,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> Galectin-3 is a multifunctional protein, the levels of which increase in the presence of diseases that progress with pulmonary fibrosis. This study investigated the role of galectin-3 levels in the staging and assessing of the severity of sarcoidosis. <b><i>Methods and Subjects:<\/i><\/b> Seventy-three subjects were studied; 25 were healthy individuals and 48 patients had pathologically confirmed diagnosis of sarcoidosis in which other potential causes had been ruled out. Galectin-3 levels were measured and compared in terms of such parameters as hemogram, biochemistry, age, body mass index, and smoking status. <b><i>Results:<\/i><\/b> The mean galectin-3 levels of the sarcoidosis patients (14.87 \u00b1 5.57) were significantly higher than those in the healthy subjects (11.81 \u00b1 2.67), and the mean galectin-3 levels differed significantly among different stages of the disease (<i>p<\/i> &#x3c; 0.05). The serum galectin-3 level in patients with stage 2, 3, and 4 sarcoidosis was found to be higher than in patients with stage 0 and 1 sarcoidosis and the control group. In addition, serum galectin-3 levels in the sarcoidosis patients had significant positive correlations with blood urea nitrogen, alkaline phosphatase, white blood cells, red blood cell, hemoglobin, and neutrophil levels (34.9% [<i>p<\/i> &#x3c; 0.05]; 40.1% [<i>p<\/i> &#x3c; 0.05]; 41.2% [<i>p<\/i> &#x3c; 0.01]; 43.3% [<i>p<\/i> &#x3c; 0.01]; 34.7% [<i>p<\/i> &#x3c; 0.05]; and 40.6% [<i>p<\/i> &#x3c; 0.01], respectively) and a significant negative correlation with the platelet distribution width levels (<i>p<\/i> &#x3c; 0.05). <b><i>Conclusion:<\/i><\/b> Serum galectin-3 levels are significantly elevated in sarcoidosis patients with parenchymal involvement at stage 2 or higher, suggesting that serum galectin-3 levels can be used to estimate disease severity in sarcoidosis. <\/jats:p>","DOI":"10.1159\/000521467","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T22:00:31Z","timestamp":1639692031000},"page":"59-65","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Serum Galectin-3 Levels in Patients with Sarcoidosis"],"prefix":"10.1159","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-2497","authenticated-orcid":false,"given":"Kaan","family":"Kara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda","family":"Tural Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Nedime Sokucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Kahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cengiz","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2933-3119","authenticated-orcid":false,"given":"Evin","family":"Ademoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00059103"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2006.11.036"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(17)31891-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(17)41797-2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1023\/B:GLYC.0000014088.21242.e0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03538-0"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00794.x"}],"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:40:31Z","timestamp":1745422831000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000521467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,11]]},"published-print":{"date-parts":[[2022,3,14]]}},"URL":"https:\/\/doi.org\/10.1159\/000521467","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"value":"1011-7571","type":"print"},{"value":"1423-0151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}